Bispecific ADCs could unlock thousands of new cancer targets A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not. Written byAndrea Corona

Bispecific ADCs could unlock thousands of new cancer targets A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not. Written byAndrea Corona https://www.drugdiscoverynews.com/bispecific-adcs-could-unlock-thousands-of-new-cancer-targets-17476?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--2BV8-1spOnQCwF3hCAIgvBdNFU4u3FkhPnUWADKW2jfOIQIMcNsl-MeKDYuEGVSCI64Y2Ze5KYIbw61P4v79GknLiAA&_hsmi=436145935&utm_content=436145935&utm_source=hs_email Antibody-drug conjugates have transformed oncology over the past decade, but they have been working with a limited playbook. The same small set of validated ADCs — including HER2, TROP2, NECTIN4, cMET and a few others — has anchored most ADC programs, not because researchers lack ambition, but because the biology of what makes a safe ADC target is genuinely constrained.